Real-world data on stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area (PACIFIC AA)

Study identifier:D4194R00023

ClinicalTrials.gov identifier:NCT04529564

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area.

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

106

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 12 Jun 2020
Primary Completion Date: 29 Jun 2023
Study Completion Date: 29 Jun 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria